Vertex (VRTX) SVP Kristen Ambrose Receives RSU Award

What Happened

• Kristen Ambrose, Senior Vice President & Chief Accounting Officer of Vertex Pharmaceuticals (VRTX), received a grant of 5,000 restricted stock units (RSUs) on 2026-08-28. The Form 4 reports the acquisition value as $0 (award/grant).
• This was a compensation award (not an open-market purchase or sale) and therefore does not represent an immediate cash investment or disposition by the insider. The RSUs vest on 03/01/2029 per the filing footnote.

Key Details

• Transaction date: 2026-08-28; Form 4 filed: 2026-09-01 (timely within the two-business-day requirement).
• Transaction type/code: A — Award/Grant of restricted stock units.
• Amount: 5,000 RSUs; reported acquisition value: $0.
• Vesting: Footnote F1 — RSU award vests on 03/01/2029.
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding, or sale noted in this Form 4.

Context

• RSUs are a common form of equity compensation that convert to actual shares only if vesting conditions are met; they require no cash outlay at grant. Because this is a compensation grant, it’s routine and not a direct bullish or bearish trading signal by itself.